激动剂和抑制剂
在生物化学和药物化学领域中,激动剂和抑制剂是调节受体活性的重要分子类型。
激动剂:激动剂是指能够与特定受体结合并激活该受体,从而引起细胞内信号传递的化合物。它们通过与受体的特定位点相互作用,模拟天然配体的功能,导致生物效应的发生或增强。根据其对受体的作用机制不同,激动剂可以分为完全激动剂和部分激动剂。
完全激动剂:能够完全激活受体,达到最大生物活性。
部分激动剂:仅能部分地激活受体,即使在高浓度下也不表现出最大效应。
抑制剂:抑制剂则是相反的一类分子,它们通过与受体或其相关蛋白质结合来阻止信号传导过程。根据作用机制的不同,可以分为竞争性抑制剂和非竞争性抑制剂。
竞争性抑制剂:这些物质通过占据活性位点而减少激动剂的结合能力,通常可以通过增加激动剂浓度来克服这种抑制效应。
非竞争性抑制剂:这类抑制剂不依赖于受体结合部位,而是通过其他方式干扰信号传递,如改变受体构象或直接与G蛋白相互作用。
在药物研发过程中,激动剂和抑制剂的研究至关重要。它们不仅用于治疗疾病,还可以帮助理解生物系统的工作原理。例如,在神经科学领域,激动剂可以被用作治疗抑郁、焦虑等精神疾病的药物;而在癌症研究中,则可能使用抑制剂来阻断促进肿瘤生长的信号通路。
中文名称 | 英文名称 | CAS号 | 化学式 | 结构式图片 |
---|---|---|---|---|
—— | Avermectin A1a, 25-cyclohexyl-4'-O-de(2,6-dideoxy-3-O-methyl--L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)- | 165108-07-6 | C43H63NO11 |
|
—— | benzyl N-[(2R)-3-methyl-1-oxo-1-[[(2R)-1-oxo-3-phenylpropan-2-yl]amino]butan-2-yl]carbamate | 88191-84-8 | C22H26N2O4 |
|
—— | 1-[(Z)-(4-chlorophenyl)methylideneamino]-2-[(E)-(4-chlorophenyl)methylideneamino]guanidine | 25875-51-8 | C15H13Cl2N5 |
|
—— | GSK525768A | 1260530-25-3 | C22H22ClN5O2 |
|
—— | Syk Inhibitor IV, BAY 61-3606 | 648903-57-5 | C20H19ClN6O3 |
|
—— | [(3~{S},4~{S})-3-methoxyoxan-4-yl]-[(1~{R},3~{S})-3-propan-2-yl-3-[[3-(trifluoromethyl)-7,8-dihydro-5~{H}-1,6-naphthyridin-6-yl]carbonyl]cyclopentyl]azanium | 624733-88-6 | C24H35F3N3O3+ |
|
—— | P-P-Ura-LRibf.2Na+ | 27821-45-0 | C9H12N2Na2O12P2 |
|
—— | GSK-3117391 | 1018673-42-1 | C22H33N3O4 |
|
—— | Pharmakon1600-01503255 | 2375-03-3 | C26H34NaO8+ |
|
—— | Ethanone, 1-(7,8-dihydro-2-((9-(trans-4-methylcyclohexyl)-9H-pyrido(4',3':4,5)pyrrolo(2,3-d)pyrimidin-2-yl)amino)-1,6-naphthyridin-6(5H)-yl)-2-hydroxy- | 1401033-86-0 | C26H29N7O2 |
|
—— | (Thiene-2,5-diyl)bis(methylene) dicarbamimidothioate--hydrogen chloride (1/1) | 2076-91-7 | C8H13ClN4S3 |
|
—— | L-Valinamide,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(2-thiazolyl)ethyl] amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R*(R*),2S*],2R*[1S*,2S*,3(R*)]]]- | 110417-88-4 | C42H68N6O6S |
|
—— | Blenoxane (TN) (Bristol Meyers) | 9041-93-4 | C55H85N17O25S4 |
|
—— | Sancycline | 808-26-4 | C21H22N2O7 |
|
—— | (2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6R)-6-[[(3S,8R,9R,10S,11R,13R,14S,17R)-17-[(2R,5R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4-dihydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol | 89590-98-7 | C66H112O34 |
|
—— | Vidofludimus calcium anhydrous | 717824-30-1 | C40H34CaF2N2O8 |
|
—— | (R)-(+)-Etomoxir sodium salt | 828934-41-4 | C15H18ClNaO4 |
|
—— | Lefamulin | 1061337-51-6 | C28H45NO5S |
|
—— | 3-Acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2,3,6-trideoxy-3-[({[4-(beta-D-galactopyranosyloxy)-3-nitrophenyl]methoxy}carbonyl)amino]-alpha-L-lyxo-hexopyranoside | 290304-24-4 | C41H44N2O20 |
|
—— | Potassium O-[(3aR,4R,5S,7R)-octahydro-1H-4,7-methanoinden-5-yl] carbonodithioate | 1096687-52-3 | C11H15KOS2 |
|
—— | Sodium 5-chloro-3-(ethyl(phenyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate | 248282-07-7 | C19H17ClN2NaO3 |
|
—— | Bavisant (dihydrochloride) | 929622-09-3 | C19H29Cl2N3O2 |
|
—— | CC-115 hydrochloride | 1300118-55-1 | C16H17ClN8O |
|
—— | 20,25-Diazacholesterol hydrochloride | 1249-84-9 | C25H45ClN2O |
|
—— | RGX-104 | 610318-03-1 | C34H33ClF3NO3*ClH |
|
—— | Quarfloxin, (R)- | 783361-78-4 | C35H33FN6O3 |
|
—— | Phenylalanyl-leucyl-leucyl-arginyl-asparagine | 141136-84-7 | C31H51N9O7 |
|
—— | 5-Methylcyclocytidine hydrochloride | 51391-96-9 | C10H14ClN3O4 |
|
—— | (2R)-3-[(2S,8S)-2-[(E)-4-[(2S,2'R,4aS,6R,8aR)-4-hydroxy-2-[1-hydroxy-3-[(2S)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-11-hydroxy-4-methyl-1,7-dioxaspiro[5.5]undec-4-en-8-yl]-2-hydroxy-2-methylpropanoic acid | 78111-17-8 | C44H68O13 |
|
—— | 1-(6-chloro-5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid | 1193383-09-3 | C12H6ClF3N4O3 |
|
—— | MG-132 | 1211877-36-9 | C26H41N3O5 |
|
—— | Sonidegib Phosphate | 1218778-77-8 | C26H32F3N3O11P2 |
|
—— | Varenicline dihydrochloride | 249296-44-4 | C13H15Cl2N3 |
|
—— | (2R)-3-[(2R,6R,8S,11R)-2-[(E,2R)-4-[(2S,2'R,4R,4aS,6S,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(2S,3R,6S)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-11-hydroxy-4-methyl-1,7-dioxaspiro[5.5]undec-4-en-8-yl]-2-hydroxy-2-methylpropanoic acid | 78111-17-8 | C44H68O13 |
|
—— | Prexasertib dihydrochloride | 1234015-54-3 | C18H21Cl2N7O2 |
|
—— | 1-(1-[(2S)-2-hydroxypropanoyl]piperidin-4-yl)-3-methyl-8-(6-methylpyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c][1,5]naphthyridin-2-one | 1220699-06-8 | C24H26N6O3 |
|
—— | (2R)-3-[(2S,6R,8S,11R)-2-[(E,1R)-3-[(2S,2'R,4R,6R,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(3R,6S)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-3-methylene-spiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-tetrahydrofuran]-2'-yl]-1-methyl-allyl]-11-hydroxy-4-methyl-1,7-dioxaspiro[5.5]undec-4-en-8-yl]-2-hydroxy-2-methyl-propanoic acid | 78111-17-8 | C44H68O13 |
|
—— | (1-(3,4-difluorobenzyl)-2-oxo-N-{1(R)-2-[(2-oxo2,3-dihydro-1H-benzimidazol-5-yl)oxy]-1-phenylethyl}-1,2-dihydropyridine-3-carboxamide) | 1001409-50-2 | C28H22F2N4O4 |
|
—— | Ro 67-7476 | 298690-60-5 | C17H18FNO2S |
|
—— | (2R)-2-hydroxy-3-[(6R)-11-hydroxy-2-[4-[(6R)-4-hydroxy-2-[1-hydroxy-3-[(6S)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-4-methyl-1,7-dioxaspiro[5.5]undec-4-en-8-yl]-2-methylpropanoic acid | 78111-17-8 | C44H68O13 |
|
—— | Gadolinium-DO3A-butriol | 138071-82-6 | C18H31GdN4O9 |
|
—— | (5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane];hydrate;dihydrochloride | 153504-70-2 | C20H38Cl2N2O3S2 |
|
—— | methyl N-[(2R)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2R)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate | 1192224-24-0 | C26H43N5O7 |
|
—— | But-2-enedioic acid--4-[(1S,2R)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol (1/1) | 169274-78-6 | C26H33NO6 |
|
—— | (1R,3S,5Z)-5-[(2E)-2-[(1R,7Ar)-1-[(2R)-5-cyclopropyl-5-hydroxypentan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol | 129831-99-8 | C27H42O3 |
|
—— | PF-543 (Citrate) | 1415562-83-2 | C33H39NO11S |
|
—— | (1aR,5S,8S,10R,22aR)-N-[(R-1R,2S)-1-[(cyclopropylsulfonamido)carbonyl]-2-ethenylcyclopropyl]-14-methoxy-5-(2-methylpropan-2-yl)-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide hydrate | 1350462-55-3 | C38H50N6O9S*H2O |
|
—— | D-Erythro-pentitol, 1,5-anhydro-2,3-dideoxy-3-(((1R,3S)-3-((7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl)carbonyl)-3-(1-methylethyl)cyclopentyl)amino)-4-o-methyl- | 624733-88-6 | C24H36F3N3O2 |
|
—— | Tricyclo(3.3.1.13,7)decane-1-carboxamide, 3-(4-chlorophenyl)-N-(4-pyridinylmethyl)- | 915385-81-8 | C23H25ClN2O |
|
—— | (2S,3R,4R)[[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl]-1-oxo-3-phenylpropyl]-amino]acetic acid dihydrate | 170098-38-1 | C25H32N2O4*2H2O |
|